Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

AHS Cancer Control Alberta

Status: Active, not recruiting

Conditions: Neuroendocrine Tumors, NET

Treatments: Drug: Lu-177 DOTA-TATE

Study type: Observational

Funder types: Other

Identifiers

NCT01763554

REV-LUT-001

Details and patient eligibility

About

Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.

Enrollment: 115 estimated patients

Sex: All

Ages: 14 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.